Literature DB >> 24533285

Recent highlights in anti-protozoan drug development and resistance research.

Frederick S Buckner1, Norman C Waters2, Vicky M Avery3.   

Abstract

This article summarizes the highlights of research presented in January, 2012, at the Keystone Symposium on "Drug Discovery for Protozoan Parasites" held in Santa Fe, New Mexico. This symposium which convenes approximately every 2 years provides a forum for leading investigators around the world to present data covering basic sciences to clinical trials relating to anti-protozoan drug development and drug resistance. Many talks focused on malaria, but other protozoan diseases receiving attention included African sleeping sickness, Chagas disease, leishmaniasis, cryptosporidiosis, and amoebiasis. The new research, most of it unpublished, provided insights into the latest developments in the field.

Entities:  

Keywords:  Antiparasitic drug discovery; Drug resistance; Malaria; Protozoa

Year:  2012        PMID: 24533285      PMCID: PMC3862445          DOI: 10.1016/j.ijpddr.2012.05.002

Source DB:  PubMed          Journal:  Int J Parasitol Drugs Drug Resist        ISSN: 2211-3207            Impact factor:   4.077


  6 in total

Review 1.  Drug-resistant malaria: molecular mechanisms and implications for public health.

Authors:  Ines Petersen; Richard Eastman; Michael Lanzer
Journal:  FEBS Lett       Date:  2011-04-23       Impact factor: 4.124

Review 2.  Artemisinin antimalarials: mechanisms of action and resistance.

Authors:  S R Meshnick
Journal:  Med Trop (Mars)       Date:  1998

3.  Spiroindolones, a potent compound class for the treatment of malaria.

Authors:  Matthias Rottmann; Case McNamara; Bryan K S Yeung; Marcus C S Lee; Bin Zou; Bruce Russell; Patrick Seitz; David M Plouffe; Neekesh V Dharia; Jocelyn Tan; Steven B Cohen; Kathryn R Spencer; Gonzalo E González-Páez; Suresh B Lakshminarayana; Anne Goh; Rossarin Suwanarusk; Timothy Jegla; Esther K Schmitt; Hans-Peter Beck; Reto Brun; Francois Nosten; Laurent Renia; Veronique Dartois; Thomas H Keller; David A Fidock; Elizabeth A Winzeler; Thierry T Diagana
Journal:  Science       Date:  2010-09-03       Impact factor: 47.728

4.  Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.

Authors:  Erin Milner; Sean Gardner; Jay Moon; Kristina Grauer; Jennifer Auschwitz; Ian Bathurst; Diana Caridha; Lucia Gerena; Montip Gettayacamin; Jacob Johnson; Michael Kozar; Patricia Lee; Susan Leed; Qigui Li; William McCalmont; Victor Melendez; Norma Roncal; Richard Sciotti; Bryan Smith; Jason Sousa; Anchalee Tungtaeng; Peter Wipf; Geoffrey Dow
Journal:  J Med Chem       Date:  2011-08-22       Impact factor: 7.446

5.  Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.

Authors:  Susan A Charman; Sarah Arbe-Barnes; Ian C Bathurst; Reto Brun; Michael Campbell; William N Charman; Francis C K Chiu; Jacques Chollet; J Carl Craft; Darren J Creek; Yuxiang Dong; Hugues Matile; Melanie Maurer; Julia Morizzi; Tien Nguyen; Petros Papastogiannidis; Christian Scheurer; David M Shackleford; Kamaraj Sriraghavan; Lukas Stingelin; Yuanqing Tang; Heinrich Urwyler; Xiaofang Wang; Karen L White; Sergio Wittlin; Lin Zhou; Jonathan L Vennerstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

6.  Mefloquine induces dose-related neurological effects in a rat model.

Authors:  G Dow; R Bauman; D Caridha; M Cabezas; F Du; R Gomez-Lobo; M Park; K Smith; K Cannard
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

  6 in total
  8 in total

1.  Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica.

Authors:  Fabrice F Boyom; Patrick V T Fokou; Lauve R Y Tchokouaha; Thomas Spangenberg; Alvine N Mfopa; Ruffin M T Kouipou; Cedric J Mbouna; Valerie F Donkeng Donfack; Paul H A Zollo
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

Review 2.  Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversification.

Authors:  James J Sahn; Brett A Granger; Stephen F Martin
Journal:  Org Biomol Chem       Date:  2014-08-19       Impact factor: 3.876

Review 3.  [Malarial antigens in the era of mRNA vaccines].

Authors:  Yannick Borkens
Journal:  Monatsschr Kinderheilkd       Date:  2022-07-14       Impact factor: 0.416

Review 4.  Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases.

Authors:  Anjan Debnath; Momar Ndao; Sharon L Reed
Journal:  Gut Microbes       Date:  2012-11-08

5.  Searching for new drugs for Chagas diseases: triazole analogs display high in vitro activity against Trypanosoma cruzi and low toxicity toward mammalian cells.

Authors:  Robson Xavier Faria; Daniel Tadeu Gomes Gonzaga; Paulo Anastácio Furtado Pacheco; André Luis Almeida Souza; Vitor Francisco Ferreira; Fernando de Carvalho da Silva
Journal:  J Bioenerg Biomembr       Date:  2018-02-23       Impact factor: 2.945

Review 6.  Recent advances in Entamoeba biology: RNA interference, drug discovery, and gut microbiome.

Authors:  Pedro Morgado; Dipak Manna; Upinder Singh
Journal:  F1000Res       Date:  2016-10-26

Review 7.  Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis.

Authors:  John G M Mina; P W Denny
Journal:  Parasitology       Date:  2017-06-22       Impact factor: 3.234

8.  Amaryllidaceae plants: a potential natural resource for the treatment of Chagas disease.

Authors:  Nieves Martínez-Peinado; Nuria Cortes-Serra; Luciana R Tallini; Maria-Jesus Pinazo; Joaquim Gascon; Jaume Bastida; Julio Alonso-Padilla
Journal:  Parasit Vectors       Date:  2021-06-26       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.